Valeritas presents CBD h-Patch data from preclinical pharmacokinetic study
Valeritas Holdings announced positive data from a preclinical pharmacokinetic study of cannabidiol subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch technology. CBD was detected within one hour of the start of infusion, followed by prolonged elimination with near steady state levels still detectable 24 hours after completion of h-Patch infusion, or 48 hours in total. These data demonstrated that subcutaneous infusion of CBD of 40mg with the h-Patch provided peak plasma levels on par with published human dose-normalized plasma concentrations from a single oral administration of 300mg CBD. Valeritas' h-Patch is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Company's V-Go is the an FDA-approved product that utilizes the h-Patch technology. To date, more than 20M V-Go insulin delivery devices have been sold in the United States.